The forecasted mortality rate for bladder malignant neoplasms in the US remains constant at 4.9 deaths per hundred thousand persons annually from 2024 to 2028. This stability reflects no expected change in the mortality rate compared to 2023, where the rate stood at 4.9 as well. As such, there's a 0% year-on-year variation and a 0% compound annual growth rate (CAGR) over the five-year forecasted period, indicating a plateau in the mortality rate.
Future trends to watch:
- Advancements in early detection and treatment technologies could impact mortality rates.
- Changes in healthcare policy and access to care might influence future statistics.
- Ongoing research and innovation in cancer treatment may offer potential outcomes in altering these forecasts.
